Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $40.7K | $63.6K | $433K | $223K | $315K | $723K | $255K | $226K | $464K | $706K |
| Revenue growth | — | 56.3% | 580.9% | -48.6% | 41.4% | 129.6% | -64.7% | -11.4% | 105.2% | 52.0% |
| Gross profit | -$4.90K | $33.9K | $408K | $200K | $215K | $547K | $184K | $195K | $459K | $703K |
| Gross margin | -12.0% | 53.3% | 94.2% | 89.7% | 68.4% | 75.7% | 71.9% | 86.1% | 99.0% | 99.6% |
| Operating income | -$1.28M | — | — | — | — | -$5.69M | -$6.62M | -$6.53M | -$5.75M | -$11.9M |
| Operating margin | -3136.8% | — | — | — | — | -786.8% | -2591.7% | -2888.5% | -1239.2% | -1683.0% |
| Net income | -$1.28M | -$1.93M | -$6.61M | -$4.16M | -$4.08M | -$4.03M | -$7.27M | -$6.66M | -$5.80M | -$11.9M |
| Net margin | -3136.8% | -3031.9% | -1525.4% | -1868.0% | -1297.6% | -557.2% | -2846.3% | -2946.4% | -1248.2% | -1686.0% |
| EPS (diluted) | -$0.03 | -$0.03 | -$0.09 | -$0.05 | -$1.47 | -$0.95 | — | -$1.01 | -$0.47 | -$0.66 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$661K | -$1.55M | -$2.52M | -$3.01M | -$2.62M | -$3.99M | -$4.88M | -$5.88M | -$4.96M | -$10.5M |
| Capital expenditures | $3.09K | $0.00 | — | $646K | $0.00 | — | $49.2K | $33.7K | $43.0K | $24.6K |
| Free cash flow | -$664K | -$1.55M | — | -$3.65M | -$2.62M | — | -$4.93M | -$5.91M | -$5.00M | -$10.5M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $93.4K | $2.53M | $1.73M | $1.29M | $1.29M | $10.9M | $5.81M | $1.35M | $6.50M | $1.80M |
| Total assets | $567K | $2.86M | $2.43M | $2.68M | $2.83M | $13.3M | $7.83M | $3.08M | $8.87M | $4.18M |
| Total liabilities | $479K | $92.3K | $43.6K | $185K | $346K | $203K | $201K | $404K | $1.21M | $1.57M |
| Shareholders' equity | $266K | $2.77M | $2.39M | $2.49M | $2.48M | $13.3M | $7.95M | $3.04M | $8.04M | $2.99M |
| Retained earnings | -$11.3M | -$13.2M | -$19.8M | -$23.9M | -$27.8M | -$31.8M | -$39.1M | -$45.8M | -$51.6M | -$63.5M |
| Shares (wtd avg diluted) | 51.3M | 68.0M | 75.5M | 78.8M | 3.00M | 5.73M | 5.95M | 6.61M | 12.4M | 18.0M |
Every figure is extracted from Lexaria Bioscience Corp.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.